Morphothiadine Mesylate |
GLS4JHS; GLS-4 |
Phase 3 Clinical |
South China Center For Innovative Pharmaceuticals, Guangdong Dongyangguang Pharmaceutical Co Ltd |
Hepatitis B, Chronic; Hepatitis B |
Details
|
GS-1720/GS-4182 |
GS-1720/GS-4182 |
Phase 3 Clinical |
Gilead Sciences Inc |
HIV Infections |
Details
|
Bictegravir/Lenacapavir sodium |
|
Phase 3 Clinical |
Gilead Sciences Inc |
HIV Infections |
Details
|
GS-4182 |
GS-4182 |
Phase 3 Clinical |
Gilead Sciences Inc |
HIV Infections |
Details
|
Lenacapavir/Islatravir |
MK-8591D |
Phase 3 Clinical |
Merck & Co Inc, Gilead Sciences Inc |
HIV Infections |
Details
|
Azodicarbonamide |
HPH-116; NSC-674447 |
Phase 2 Clinical |
H-Phar Pharmaceuticals |
HIV Infections |
Details
|
QL-007 |
QL-007 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Hepatitis B, Chronic |
Details
|
GST-HG141 |
GST-HG141 |
Phase 2 Clinical |
Fujian Cosunter Pharmaceutical Co Ltd |
Hepatitis B, Chronic; Hepatitis B |
Details
|
bersacapavir |
JNJ-56136379; JNJ-379; JNJ-6379; 14C JNJ-56136379 |
Phase 2 Clinical |
Johnson & Johnson |
Hepatitis, Chronic; Hepatitis B, Chronic; Renal Insufficiency; Hepatitis B; Hepatic Insufficiency |
Details
|
RO-7049389 |
RO-7049389 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Hepatitis B, Chronic |
Details
|
Traxivitug |
MAU-868 |
Phase 2 Clinical |
Novartis Pharma Ag |
BK Polyomavirus Infections; Polyomavirus Infections |
Details
|
Vebicorvir |
ABI-H0731; ABIH-0731 |
Phase 2 Clinical |
Indiana University |
Hepatitis B, Chronic; Hepatitis B |
Details
|
Canocapavir |
ZM-H1505R; CB-001; CB-01 |
Phase 2 Clinical |
Shanghai Zhimeng Biopharma Inc |
Hepatitis B, Chronic; Hepatitis B |
Details
|
VH-4011499 |
VH-4011499; GSK-4011499; VH-4011499-A; VH-499 |
Phase 2 Clinical |
Viiv Healthcare |
HIV Infections |
Details
|
VH-4004280 |
VH-4004280; VH 4004280A |
Phase 2 Clinical |
Viiv Healthcare |
HIV Infections |
Details
|
Firzacorvir |
2158; ABI-2158; ABI-H2158 |
Phase 2 Clinical |
Assembly Biosciences Inc, Indiana University |
Hepatitis B, Chronic |
Details
|
BIT-225 |
BIT-225 |
Phase 2 Clinical |
Biotron |
HIV Infections; Hepatitis C |
Details
|
Fipravirimat |
BMS-986197; GSK-3640254 |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
HIV Infections |
Details
|
AB-423 |
AB-423 |
Phase 1 Clinical |
Arbutus Biopharma Corp |
Hepatitis B |
Details
|
H-05(Protheragen) |
|
Phase 1 Clinical |
Protheragen Inc |
Hepatitis B |
Details
|
EV68-228-N |
EVD68-228N; EVD68-228-N; EV68-228-N; KB-13-A |
Phase 1 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid), KBio Inc |
Enterovirus Infections; Acute Flaccid Myelitis |
Details
|
PLD-401 |
PLD-401 |
Phase 1 Clinical |
Pelemed Co Ltd |
Hepatitis B, Chronic |
Details
|
Morphothiadine Mesylate/Ritonavir |
|
Phase 1 Clinical |
Guangdong Dongyangguang Pharmaceutical Co Ltd |
Hepatitis B, Chronic |
Details
|
LW-231 |
LW-231 |
Phase 1 Clinical |
Shanghai Longwood Biopharmaceuticals Co Ltd |
Hepatitis B, Chronic |
Details
|
ALG-010184 |
ALG-010184 |
Phase 1 Clinical |
Aligos Therapeutics Inc |
Hepatitis B, Chronic |
Details
|
ALG-000184 |
ALG-000184 |
Phase 1 Clinical |
Aligos Therapeutics Inc |
Hepatitis B, Chronic |
Details
|
XT-1061 |
XTYW-001; XTYW001; XT-1061; XT1061 |
Phase 1 Clinical |
Xi'an Xintong Pharmaceutical Research Co Ltd |
Hepatitis B, Chronic |
Details
|
GS-CA2 |
GS-CA2; GS-CA-2 |
Phase 1 Clinical |
Gilead Sciences Inc |
HIV Infections |
Details
|